Literature DB >> 9931080

Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure.

A Benetos1, A Rudnichi, F Thomas, M Safar, L Guize.   

Abstract

-The aim of the present study was to assess the effects of high heart rate on mortality in different subgroups in a French population according to age, gender, and blood pressure levels. We studied 19 386 subjects (12 123 men, 7263 women), aged 40 to 69 years, who had a routine health examination at the Centre d'Investigations Préventives et Cliniques (IPC) between 1974 and 1977. Heart rate (HR) measured by ECG was classified into 4 groups: HR1, <60; HR2, 60 to 80; HR3, 81 to 100; and HR4, >100 bpm. Mortality data were recorded for the period of 1974 through 1994. In both sexes, HR was a significant predictor of noncardiovascular mortality. In men, the relative risk (95% confidence interval) for cardiovascular death after adjustment for age and other risk factors in the HR2, HR3, and HR4 groups was 1.35 (1.01 to 1.80), 1.44 (1.04 to 2.00), and 2.18 (1.37 to 3.47), respectively, when compared with HR1. In women, HR did not influence cardiovascular mortality. The association of HR with cardiovascular mortality in men was (1) related to a strong association with coronary but not cerebrovascular mortality, (2) independent of age and hypertension, and (3) influenced by the level of pulse pressure; in patients with high pulse pressure (>65 mm Hg), accelerated HR was not associated with increased cardiovascular mortality. In conclusion, in a large French population, accelerated resting HR represents an independent predictor of noncardiovascular mortality in both genders, and of cardiovascular mortality in men, independent of age and the presence of hypertension. Further investigations are needed to explain the complex interactions between HR, pulse pressure, and cardiovascular complications.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9931080     DOI: 10.1161/01.hyp.33.1.44

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  87 in total

Review 1.  Exploring HCN channels as novel drug targets.

Authors:  Otilia Postea; Martin Biel
Journal:  Nat Rev Drug Discov       Date:  2011-11-18       Impact factor: 84.694

Review 2.  The prognostic significance of heart rate for cardiovascular disease and hypertension.

Authors:  Trygve B Tjugen; Arnljot Flaa; Sverre E Kjeldsen
Journal:  Curr Hypertens Rep       Date:  2010-06       Impact factor: 5.369

3.  Association between resting heart rate and cardiovascular mortality: evidence from a meta-analysis of prospective studies.

Authors:  Yuechun Li
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Resting heart rate and all-cause and cardiovascular mortality in the general population: a meta-analysis.

Authors:  Dongfeng Zhang; Xiaoli Shen; Xin Qi
Journal:  CMAJ       Date:  2015-11-23       Impact factor: 8.262

5.  Heart rate and microinflammation in men: a relevant atherothrombotic link.

Authors:  O Rogowski; I Shapira; A Shirom; S Melamed; S Toker; S Berliner
Journal:  Heart       Date:  2007-01-19       Impact factor: 5.994

Review 6.  Perspectives of I(f) inhibition by ivabradine in cardiology.

Authors:  Michael Böhm; Jan-Christian Reil
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 7.  The funny current: cellular basis for the control of heart rate.

Authors:  Dario DiFrancesco; Jeffrey S Borer
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 8.  Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms.

Authors:  Paolo Palatini
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 9.  Clinical results of I(f) current inhibition by ivabradine.

Authors:  Jean-Claude Tardif
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 10.  Cardiovascular safety of beta(2)-adrenoceptor agonist use in patients with obstructive airway disease: a systematic review.

Authors:  Shelley R Salpeter
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.